Hemostatic Agents gather Steam for Managing Surgical Bleeding in Patient Populations
Published On : Dec 19, 2018 | Category : Healthcare
The drive for hemostatic agents stems from the need for efficacious hemostatics for surgical dressings, especially for post-traumatic injuries. These agents have gained traction in the surgical settings as an adjunct or alternative to surgical techniques for managing bleeding from surgical surfaces, particularly when the use of latter is not practical or viable. For instance, these agents are especially useful in patients with hemostatic abnormalities or in case of diffuse non-anatomic bleeding. Haemorrhage is a cause of trauma-associated death in worldwide populations and hemostatic agents play a key role in establishing establish hemostasis. The global hemostatic agents market gained momentum from the adoption of hemostatic agents in managing bleeding from surgical surfaces. World over, they are extensively used in large hospitals.
The growing instance of surgical bleeding in patients is a key factor accentuating the demand for hemostatic agents. Recent advancements in mechanism for hemostatics have made hemostatic agents more effective and safer in a variety of surgical procedures. This is expected to expand the prospects of the market. According to a projection by Transparency Market Research, the opportunities in the global market will reach a sizeable value of US$ 4.1 billion by the end of 2022.
Rising Use in Cardiology Surgeries bolster Uptake of Hemostatic Agents
The various therapeutic areas where hemostatic agents used are cardiology, trauma, cath lab, general surgery, OB/GYN, oncology, neurology, transplant, orthopedic, dental, and plastic surgery. Of these, the combined share of cardiology, trauma, and general surgery is greater than all others. The substantial uptake of hemostatic agents in these therapeutic areas is attributed to the rising number of these procedures. The growing mortality associated with bleeding in cardiology treatments in various parts of the world has been bolstering the demand for various hemostatic agents. The growing prevalence of coronary heart diseases is also catalyzing the demand for hemostatic agents to manage bleeding in cardiovascular processes.
Out of various types of hemostatic agents, thrombin-based hemostats have gained wide traction as they have better efficacy in all therapeutic areas, especially where the bleeding is large. They act rapidly on the coagulation process.
Developed and Developing Regions display Substantial Potential for Growth
The various key regional markets for hemostatic agents are North America, Asia Pacific, South Africa, Europe, and a region called rest of the world (RoW). Of these, presently North America leads the pack and is expected to retain its sway at least till the end of the forecast period that is until 2022. The growth is driven by the rising demand or hemostatic agents among elderly populations and the constant flux of new products. Moreover, increasing focus on product innovations in the region, coupled with increasing number of prominent companies, are constantly creating lucrative market avenues in the region.
On the other hand, burgeoning population base and rapid research and developments in the medical sector, combined with improvements in healthcare services, are factors that will make Asia Pacific to expand at the most attractive pace during the assessment period. Efforts taken by clinicians to bring down the mortality rate due to traumatic injuries also augurs well for the demand in the region.